Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.

  • Zhao L
  • Chen C
  • Hajji N
 et al. 
  • 26


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


BACKGROUND: Epigenetic programming, dynamically regulated by histone acetylation, is a key mechanism regulating cell proliferation and survival. Little is known about the contribution of histone deacetylase (HDAC) activity to the development of pulmonary arterial hypertension, a condition characterized by profound structural remodeling of pulmonary arteries and arterioles.

METHODS AND RESULTS: HDAC1 and HDAC5 protein levels were elevated in lungs from human idiopathic pulmonary arterial hypertension and in lungs and right ventricles from rats exposed to hypoxia. Immunohistochemistry localized increased expression to remodeled vessels in the lung. Both valproic acid, a class I HDAC inhibitor, and suberoylanilide hydroxamic acid (vorinostat), an inhibitor of class I, II, and IV HDACs, mitigated the development of and reduced established hypoxia-induced pulmonary hypertension in the rat. Both valproic acid and suberoylanilide hydroxamic acid inhibited the imprinted highly proliferative phenotype of fibroblasts and R-cells from pulmonary hypertensive bovine vessels and platelet-derived growth factor-stimulated growth of human vascular smooth muscle cells in culture. Exposure to valproic acid and suberoylanilide hydroxamic acid was associated with increased levels of p21 and FOXO3 and reduced expression of survivin. The significantly higher levels of expression of cKIT, monocyte chemoattractant protein-1, interleukin-6, stromal-derived factor-1, platelet-derived growth factor-b, and S100A4 in R-cells were downregulated by valproic acid and suberoylanilide hydroxamic acid treatment.

CONCLUSIONS: Increased HDAC activity contributes to the vascular pathology of pulmonary hypertension. The effectiveness of HDAC inhibitors, valproic acid, and suberoylanilide hydroxamic acid, in models of pulmonary arterial hypertension supports a therapeutic strategy based on HDAC inhibition in pulmonary arterial hypertension.

Author-supplied keywords

  • Animals
  • Anoxia
  • Anoxia: complications
  • Cell Proliferation
  • Cell Proliferation: drug effects
  • Cells, Cultured
  • Disease Models, Animal
  • Histone Deacetylase 1
  • Histone Deacetylase 1: antagonists & inhibitors
  • Histone Deacetylase 1: metabolism
  • Histone Deacetylase Inhibitors
  • Histone Deacetylase Inhibitors: pharmacology
  • Histone Deacetylase Inhibitors: therapeutic use
  • Histone Deacetylases
  • Histone Deacetylases: drug effects
  • Histone Deacetylases: metabolism
  • Humans
  • Hydroxamic Acids
  • Hydroxamic Acids: pharmacology
  • Hydroxamic Acids: therapeutic use
  • Hypertension, Pulmonary
  • Hypertension, Pulmonary: drug therapy
  • Hypertension, Pulmonary: etiology
  • Hypertension, Pulmonary: metabolism
  • Lung
  • Lung: drug effects
  • Lung: metabolism
  • Lung: pathology
  • Male
  • Muscle, Smooth, Vascular
  • Muscle, Smooth, Vascular: drug effects
  • Muscle, Smooth, Vascular: metabolism
  • Muscle, Smooth, Vascular: pathology
  • Platelet-Derived Growth Factor
  • Platelet-Derived Growth Factor: pharmacology
  • Pulmonary Artery
  • Pulmonary Artery: drug effects
  • Pulmonary Artery: metabolism
  • Pulmonary Artery: pathology
  • Rats
  • Rats, Sprague-Dawley
  • Valproic Acid
  • Valproic Acid: pharmacology
  • Valproic Acid: therapeutic use

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • Lan Zhao

  • Chien-Nien Chen

  • Nabil Hajji

  • Eduardo Oliver

  • Emanuele Cotroneo

  • John Wharton

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free